TrialEuropean journal of nuclear medicine and molecular imaging2022

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.

Aleksandra Syguła et al.PubMed ↗Publisher ↗

No numbers read from the abstract.